新型冠状病毒

FDA panel votes against Pfizer’s Covid-19 booster jab application

Advisory committee endorses third dose only for elderly and at-risk groups in blow to Biden

Scientific advisers to the US Food and Drug Administration have voted overwhelmingly against Pfizer’s application to offer a third shot of its Covid-19 vaccine to everyone over 16, dealing a serious blow to the Biden administration’s plans for a widespread booster programme.

Members of the regulator’s vaccine advisory committee voted 16-2 on Friday against endorsing a booster of the two-dose BioNTech/Pfizer vaccine for Americans aged 16 or older at least six months after receiving their second shot.

They subsequently voted unanimously to authorise a third shot only for over-65s, anyone at high risk of contracting severe Covid-19, and people whose jobs expose them to the virus, such as healthcare workers.

您已阅读15%(712字),剩余85%(4050字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×